Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highly predictive 3D-model for substituted acridines

Journal of Chemical Information and Modeling

Volumn 49, Issue 5, 2009, Pages 1298-1311

  Zambre, Vishal P ^a   Murumkar, Prashant R ^a   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3D MODELING; BIOINFORMATICS; COMPUTATIONAL CHEMISTRY; ENZYME INHIBITION; LIGANDS; PH; PHYSIOLOGICAL MODELS; PROTONATION;

ACRIDINE DERIVATIVES; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE-MOLECULAR-SIMILARITY-INDICES ANALYSIS; G-QUADRUPLEX STRUCTURE; RATIONAL DRUG DESIGNS; SELECTIVE LIGANDS; STRUCTURAL INVESTIGATION; STRUCTURAL REQUIREMENTS;

PREDICTIVE ANALYTICS;

ACRIDINE DERIVATIVE; DNA; GUANINE QUADRUPLEX; TELOMERASE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; VALIDATION STUDY;

ACRIDINES; DNA; G-QUADRUPLEXES; MODELS, MOLECULAR; TELOMERASE;

EID: 66249109269     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900036w     Document Type: Article

References (53)

1. Blackburn, E. Telomeres-no end in sight. Cell 1994, 77, 621-623.
2. Zakian, V. Telomeres-beginning to understand the end. Science 1995, 270, 1601-1607.
3. Delange, T. Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 2882-2885.
4. Bryan, T.; Cech, T. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell. Biol. 1999, 11, 318-324.
5. Harley, C.; Villeponteau, B. Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev. 1995, 5, 249-255.
6. Kim, N.; Piatyszck, M.; Prowse, K.; Harley, C.; West, M.; Ho, P. L. C.; et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266, 2011-2015.
7. Mergny, J.; Mailliet, P.; Lavelle, F.; Riou, J.; Laoui, A.; Helene, C. The development of telomerase inhibitors: G-quartet approach. Anti-Cancer Drug Des. 1999, 14, 327-339.
8. Perry, P.; Jenking, T. C. Recent advances in the development of the telomerase inhibitors for the treatment of cancer. Expert Opin. Invest. Drugs 1999, 8, 1981-2008.
9. Raymond, E.; Sorid, J. C.; Izbica, E.; Baussin, F.; Hurley, L.; Von Hoff, D. DNA G-quadruplexes, telomere-specific proteins and telomere associated enzymes as potential target for new anticancer drugs. Invest. New Drugs 2000, 18, 123-137.
10. Neidle, S.; Parkinson, G. Telomere maintenance as a target for anticancer drug discovery. Nat. Rev. Drug Discovery 2002, 1, 383-393.
11. Gellert, G.; Dikman, Z.; Wright, W.; Gryaznov, S.; Shay, J. Effect of novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 2006, 96, 73-81.
12. Blackburn, E. Switching and signaling at the telomere. Cell 2001, 106, 661-73.
13. Wright, W.; Tesmer, V.; Huffman, K.; Levene, S.; Shay, J. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 1997, 11, 2801-2809.
14. Sfeir, A.; Chai, W.; Shay, J.; Wright, W. Telomere-end processing: the terminal nucleotides of human chromosomes. Mol. Cell 2005, 18, 131-138.
15. Zaung, A.; Podell, E.; Cech, T. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 10864-10869.
16. Zahler, A.; Williamson, J.; Cech, T. Inhibition of telomerase by G-quartet DNA structures. Nature (London) 1991, 350, 718-720.
17. Oganesian, L.; Moon, I. K.; Bryan, T.; Jarstfer, M. Extension of G-quadruplex DNA by ciliate telomerase. EMBO J. 2006, 25, 1148-1159.
18. Sun, D.; Thompson, B.; Cathers, B.; Salazar, M.; Kerwin, S.; Trent, J.; Jenkins, T.; Neidle, S.; Hurley, L. Inhibition of human telomerase by a G-quadruplex interactive compound. J. Med. Chem. 1997, 40, 2113-2116.
19. Harrison, R.; Gowan, S.; Kelland, L.; Neidle, S. Human telomerase inhibition by substituted acridine derivatives. Bioorg. Med. Chem. Lett. 1999, 9, 2463-2468.
20. Read, M. A.; Wood, A.; Harrison, R.; Gowan, S.; Kelland, L.; Dosanjh, H.; Neidle, S. Molecularmodeling studies on G-quadruplex complexes of telomerase inhibitors: Structure activity relationships. J. Med. Chem. 1999, 42, 4538-4546.
21. Han, H.; Hurley, L.; Salazar, M. A DNA polymerase stop assay for G-quadruplex-interactive compounds. Nucleic Acid Res. 1999, 27, 537-542.
22. Rossetti, L.; Franceschin, M.; Blanco, A.; Ortaggi, G.; Savino, M. Perylene diimides with different side chains are selective in inducing different G-quadruplex DNA structures and in inhibiting telomerase. Bioorg. Med. Chem. Lett. 2008, 12, 2527-2533.
23. Koeppel, F.; Riou, J.; Laoui, A.; Mailliet, P.; Arimondo, P.; Labit, D.; Petitgenet, O.; Helene, C.; Mergny, J. Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. Nucleic Acid Res. 2001, 29, 1087-1096.
24. Kim, M.; Duan, W.; Gleason-Guzman, M.; Hurley, L. Design, synthesis, and biological evaluation of a series of fluoroquinoanthrox-azines with contrasting dual mechanisms of action against topoi-somerase II and G-quadruplexes. J. Med. Chem. 2003, 46, 571-583.
25. Caprio, V.; Guyen, B.; Opoku-Boahen, Y.; Mann, J.; Gowan, S.; Kelland, L.; Read, M.; Neidle, S. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg. Med. Chem. Lett. 2000, 10, 2063-2066.
26. Mergny, J.; Lacroix, L.; Teulade-Fichou, M.; Hounsou, C.; Guittat, L.; Hoarau, M.; Arimondo, P.; Vigneron, J.; Lehn, J.; Riou, J.; Garesti, T.; Helene, C. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 3062-3067.
27. Teulade-Fichou, M.; Carrasco, C.; Guittat, L.; Bailly, C.; Alberti, P.; Mergny, J.; David, A.; Lehn, J.; Wilson, W. Selective recognition of G-quadruplex telomeric DNA by a bis(quinacridine) macrocycle. J. Am. Chem. Soc. 2003, 125, 4732-4740.
28. Gowan, S.; Heald, R.; Stevens, M.; Kelland, L. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 2001, 60, 981-988.
29. Heald, R.; Modi, C.; Cookson, J.; Hulchinson, I.; Laughton, C.; Gowan, S.; Kelland, L.; Stevens, M. Antitumor polycyclic acridines. 8 (1) synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. J. Med. Chem. 2002, 45, 590-597.
30. Shin-ya, K.; Wierzba, K.; Matsuo, K.; Ohtani, T.; Yamanda, Y.; Furihata, K.; Hayakawa, Y.; Seto, H. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc. 2001, 123, 1262-1263.
31. De Cian, A.; Delemos, E.; Mergny, J. L.; Teulade-Fichou, M.; Monchoud, D. Highly efficient G-quadruplex recognition by bisquino-linium compounds. J. Am. Chem. Soc. 2007, 129, 1856-1857.
32. Pennarun, G.; Granotier, C.; Gauthier, L.; Gomez, D.; Hoffschi, F.; Mandine, E.; Riou, J.; Mergny, J.; Mailliet, P.; Boussin, F. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene 2005, 24, 2917-2928.
33. Read, M.; Harrison, R.; Ramagnoli, B.; Tanious, F.; Gowan, S.; Reszka, A. P.; Wilson, W.; Kelland, L.; Neidle, S. Structure based design of selective and potent G-quadruplex mediated telomerase inhibitors. Proc. Natl. Acad. Sci. 2001, 98, 4844-4849.
34. Harrison, R.; Cuesta, J.; Chessari, G.; Read, M.; Basra, S.; Reszka, A.; Morrell, J.; Gowan, S.; Incles, C.; Tanious, F.; Wilson, W.; Kelland, L.; Neidle, S. Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J. Med. Chem. 2003, 46, 4463-4476.
35. Schultes, C.; Guyen, B.; Cuesta, J.; Neidle, S. Synthesis, biophysical and biological evaluation of 3,6-bis-amidoacridines with extended 9-anilino substitutents as potent G-quadruplex binding telomerase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4347-4351.
36. Moore, M.; Schultes, C.; Cuesta, J.; Cuenca, F.; Gunaratnam, M.; Tanious, F.; Wilson, W.; Neidle, S. Trisubstituted acridines as G-quadruplex telomere targeting agent. Effect of extension of the 3, 6-and 9-sidechains on quadruplex binding, telomerase activity and cell proliferation. J. Med. Chem. 2006, 49, 582-599.
37. Martins, C.; Gunaratnam, M.; Stuart, J.; Makwana, V.; Greciano, O.; Reszka, A.; Kelland, L.; Neidle, S. Structure based design of benzylamini-acridine compounds as G-quadruplex DNA telomere targeting agents. Bioorg. Med. Chem. Lett. 2007, 17, 2293-2298.
38. Cramer, R., III; Patterson, D.; Bunce, J. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
39. Klebe, G.; Abraham, U.; Meitzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
40. Puntambekar, D.; Giridhar, R.; Yadav, M. 3D-QSAR CoMFA/ CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors. Acta Pharm. 2006, 56, 157-174.
41. Puntambekar, D.; Giridhar, R.; Yadav, M. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem. 2006, 41, 1279-1292.
42. Puntambekar, D.; Giridhar, R.; Yadav, M. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. Bioorg. Med. Chem. Lett. 2006, 16, 1821-1827.
43. Puntambekar, D.; Giridhar, R.; Yadav, M. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. Eur. J. Med. Chem. 2008, 43, 142-154.
44. Murumkar, P.; Giridhar, R.; Yadav, M. 3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. Chem. Biol. Drug Des. 2008, 71, 363-373.
45. Murumkar, P.; Dasgupta, S.; Zambre, V.; Giridhar, R.; Yadav, M. Development of Predictive 3D-QSAR CoMFA and CoMSIA Models for /-aminohydroxamic acid-derived TACE inhibitors. Chem. Biol. Drug Des. 2009, 73, 97-107.
46. Golbraikh, A.; Tropsha, A. Beware of q2. J. Mol. Graphics Modell. 2002, 20, 269-276.
47. SYBYL 7.0; Tripos Inc., 1699 South Hanley Road, St. Louis, Missouri 63144, U.S.A.
48. Stewart, J. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
49. Dewar, M.; Zoebisch, E.; Healy, E.; Stewart, J. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
50. Wu, G.; Robertson, D.; Brooks, C., III; Vieth, M. Detailed analysis of Grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem. 2003, 24, 1549-1562.
51. Haider, S.; Parkinson, G.; Neidle, S. Structure of G-quadruplex-ligand complex. J. Mol. Biol. 2003, 326, 117-125.
52. Devillers, J.; Lipinick, R. In Practical Applications of Quantitative-Structure Activity Reationships (QSAR) in Environmental chemistry and Toxicology, 1st ed.;Karcher, W., Devillers, J., Eds.; Kluwer: Dordrecht, 1990; Vol. 1, pp 129-143.
53. Bohm, M.; Sturzebecher, J.; Klebe, G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J. Med. Chem. 1999, 42, 458-477.